DRTS

+ Watchlist + Portfolio

Alpha Tau Medical Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $14.47
52-Week Range: $3.06 – $14.75
Market Cap: $1.33B
P/E (TTM): —
EPS (TTM): -1.04
Dividend Yield: —

Advanced Metrics

Price/Book: 18.67
PEG Ratio: —
Return on Equity: -141.68%
Return on Assets: -25.71%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 11.09
Debt/Equity: 0.34
Total Debt: $15.15M
Free Cash Flow: $-20.26M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.24B

DRTS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.89M	$26.42M	$27.02M	$32.06M
Selling, General & Admin	$11.25M	$9.26M	$9.02M	$10.22M
Operating Expenses	$32.14M	$35.68M	$36.04M	$42.29M
Operating Income	-$32.14M	-$35.68M	-$36.04M	-$42.29M
EBITDA	-$32.76M	-$27.99M	-$30.34M	-$40.93M
Pretax Income	-$33.74M	-$29.14M	-$31.74M	-$42.51M
Income Tax	$20.00K	$16.00K	$6.00K	$121.00K
Net Income	-$33.76M	-$29.16M	-$31.75M	-$42.63M
Diluted EPS	-0.53	-0.42	-0.45	-0.53
Diluted Shares	63.53M	69.38M	69.93M	80.58M

DRTS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.84M	$12.66M	$13.72M	$12.20M
Receivables	$313.00K	$344.00K	$332.00K	$336.00K
Current Assets	$106.48M	$85.76M	$64.23M	$78.30M
Total Assets	$120.15M	$107.39M	$86.20M	$105.65M
Current Liabilities	$4.34M	$7.10M	$8.68M	$10.51M
Long-Term Debt	—	$5.61M	$5.56M	$6.35M
Total Debt	$5.19M	$13.28M	$12.54M	$13.73M
Total Liabilities	$14.49M	$22.91M	$23.54M	$28.55M
Retained Earnings	-$86.60M	-$115.76M	-$147.51M	-$190.14M
Shareholders' Equity	$105.66M	$84.47M	$62.67M	$77.10M
Working Capital	$102.14M	$78.65M	$55.55M	$67.79M

DRTS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.88M	-$17.96M	-$19.78M	-$26.68M
Capital Expenditure	-$904.00K	-$6.40M	-$2.24M	-$6.08M
Free Cash Flow	-$24.78M	-$24.36M	-$22.02M	-$32.76M
Depreciation & Amortisation	$979.00K	$1.07M	$1.10M	$1.23M
Stock-Based Compensation	$6.75M	$7.93M	$9.92M	$10.62M
Investing Cash Flow	-$89.94M	$18.68M	$20.77M	-$20.59M
Financing Cash Flow	$96.91M	$5.30M	$25.00K	$45.77M
Net Change in Cash	-$16.91M	$6.02M	$1.01M	-$1.50M

DRTS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.17M	$7.01M	$8.31M	$9.58M	$10.97M
Selling, General & Admin	$2.14M	$2.64M	$2.42M	$3.03M	$2.34M
Operating Expenses	$9.31M	$9.65M	$10.73M	$12.60M	$13.31M
Operating Income	-$9.31M	-$9.65M	-$10.73M	-$12.60M	-$13.31M
EBITDA	-$9.31M	-$9.18M	-$11.20M	-$12.47M	-$13.31M
Pretax Income	-$8.59M	-$10.05M	-$11.69M	-$12.17M	-$22.95M
Income Tax	$99.00K	$65.00K	-$8.00K	-$35.00K	-$11.00K
Net Income	-$8.69M	-$10.11M	-$11.69M	-$12.14M	-$22.94M
Diluted EPS	-0.12	—	—	—	-0.26
Diluted Shares	70.45M	—	—	—	89.71M

DRTS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.02M	$11.70M	$3.33M	$12.20M	$4.64M
Receivables	$1.94M	$2.52M	$1.22M	$336.00K	$1.12M
Current Assets	$56.79M	$85.78M	$77.10M	$78.30M	$81.35M
Total Assets	$80.93M	$110.95M	$104.69M	$105.65M	$108.77M
Current Liabilities	$9.77M	$8.16M	$9.14M	$10.51M	$10.45M
Long-Term Debt	$5.47M	$6.03M	$6.15M	$6.35M	$6.40M
Total Debt	$12.29M	$13.31M	$13.50M	$13.73M	$14.34M
Total Liabilities	$24.60M	$24.33M	$27.11M	$28.55M	$39.42M
Retained Earnings	-$156.20M	-$166.31M	-$178.00M	-$190.14M	-$213.07M
Shareholders' Equity	$56.33M	$86.62M	$77.58M	$77.10M	$69.35M
Working Capital	$47.02M	$77.62M	$67.96M	$67.79M	$70.90M
Net Debt	$453.00K	—	$2.82M	—	$1.77M

Market Snapshot

About

Alpha Tau Medical Ltd. is an Israeli medical device company developing innovative cancer radiation therapy solutions. The company's Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology delivers alpha radiation directly to solid tumors through radioactive seeds. Alpha Tau's approach aims to destroy tumors while minimizing damage to surrounding healthy tissue. The technology is being studied for treating various solid tumor types including skin, head and neck, breast, and pancreatic cancers. The company is conducting clinical trials and pursuing regulatory approvals in multiple markets.